Replies to post #310 on C4 Therapeutics Inc (CCCC)

[B RY]

"Combined with savings from the layoffs and restructured operations, C4 said it now expects its cash runway to extend into 2027.

The decision to restructure the company “was not a decision we made lightly,” CEO Andrew Hirsch said in the Jan. 9 release.

“Our sharpened focus on progressing CFT7455 and CFT1946 to critical clinical milestones, along with advancing targeted protein degradation research through our discovery collaborations with Roche, Biogen and Merck and our internal research efforts, will help C4T deliver breakthrough therapies for patients with cancer and other diseases,” Hirsch added."

I don't care much for press releases alone. I like to research company operations to see if they are truly attempting to create a strong future. I've found Fierce biotech to be a good source of articles on pharmaceutical companies operations for quick research. There are many others for indepth research when time permits.

https://www.fiercebiotech.com/biotech/moderna-says-it-wont-advance-us-backed-zika-vaccine-without-more-outside-funding